Sarcopenia Prevalence Using Different Definitions in Older Community-Dwelling Canadians.


Journal

The journal of nutrition, health & aging
ISSN: 1760-4788
Titre abrégé: J Nutr Health Aging
Pays: France
ID NLM: 100893366

Informations de publication

Date de publication:
2020
Historique:
entrez: 4 8 2020
pubmed: 4 8 2020
medline: 5 2 2021
Statut: ppublish

Résumé

Sarcopenia is a debilitating condition affecting millions of individuals worldwide and is defined with different criteria. The objective of this study was to determine the prevalence of sarcopenia in older Canadians using three internationally accepted criteria. Observational cohort study. Data from 12,592 subjects [6,314 males (50.1%), 6,278 females (49.9%)] ≥65 years old in the Canadian Longitudinal Study on Aging were included. Appendicular lean mass (ALM; kg) and appendicular lean mass index (ALM kg/height in m2) were collected from dual X-ray absorptiometry measurements. Physical performance was assessed using the 4-m gait speed test, and muscle strength was measured by hand dynamometry. Sarcopenia was defined according to criteria put forth by the International Working Group on Sarcopenia (IWGS), Foundation for the National Institutes of Health (FNIH) Sarcopenia Project, and revised European Working Group on Sarcopenia in Older People (EWGSOP). Positive and negative percent agreements and Cohen's kappa (κ) described the agreement among sarcopenia definitions. Among the evaluated criteria, gait speed ≤ 1.0 m/s (IWGS definition of slowness) was the most frequently identified deficit (56.8% males, 57.2% females). The prevalence of sarcopenia ranged from 1.4 to 5.2% in males and 1.6 to 7.2 % in females among the different definitions. Positive percent agreement values among criteria were generally low (range: 1.5 - 55.3%) and corresponded to κ indicating none to minimal agreement (0.01 - 0.23). Negative percent agreement values were ≥ 95%. Sarcopenia prevalence was relatively low in older Canadian adults and current definitions had poor agreement in diagnosing individuals as sarcopenic.

Identifiants

pubmed: 32744576
doi: 10.1007/s12603-020-1427-z
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

783-790

Subventions

Organisme : CIHR
ID : LSA 9447
Pays : Canada
Organisme : CIHR
ID : FRN 151279
Pays : Canada

Déclaration de conflit d'intérêts

The authors have no conflicts of interests to declare.

Auteurs

S A Purcell (SA)

Dr. Carla Prado, Associate Professor, 4-002 Li Ka Shing Centre for Health Research Innovation (Office 2-021E), Edmonton, Alberta, Canada T6G 2E1, Tel: 780.492.7934 email: cprado@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH